June 29, 2017
GenomeDx Announces New York State CLEP Approval of Decipher Prostate Cancer Tests
June 7, 2017
Multiple Studies Further Validate the Importance of Decipher Post-Op in the Treatment of Prostate Cancer
June 1, 2017
GenomeDx’s Decipher to be Featured in Multiple Presentations at ASCO 2017
May 12, 2017
GenomeDx and Color Collaborate to Further Advance Precision Medicine for Prostate Cancer Patients and their Families
May 11, 2017
GenomeDx’s Decipher GRID Aids in Development and Validation of Molecular Subtypes in Prostate Cancer that Predict Response to Hormone Therapy
May 10, 2017
GenomeDx Launches Decipher Bladder Cancer Classifier Following Publication of Study on Development, Validation of Molecular Subtyping in Muscle-Invasive Bladder Cancer Patients
May 9, 2017
GenomeDx Appoints Michael Rodriguez as Chief Financial Officer
May 4, 2017
GenomeDx’s Decipher GRID and Decipher Tests to be Featured in Multiple Abstracts at the 112th American Urological Association Annual Meeting
April 25, 2017
GenomeDx’s Decipher Post-Op Demonstrates Positive Impact on Physician, Patient Treatment Decisions in Multicenter Prospective Study
March 24, 2017
